Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment
Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that [...]
Pain and Its Under-Treatment in Advanced Cancers
I really thought we had gotten over this problem, but an article appearing in a recent report in the Journal of Clinical Oncology indicates that the age old problem that often our doctors fail to [...]
Cabozantinib Fails In the Phase III COMET-1 Trial
The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared [...]
Thank You My Readers for Your Support in Being Awarded the Harry Pinchot Service Award
I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute. The award recognizes outstanding dedication and support to the prostate cancer community. I am [...]
Understanding the Real Concerns Men with Advanced Prostate Cancer Have About the Quality of Their Life
Advanced prostate cancer and its treatments has significant impacts on a man’s quality of life (QOL) as well as their perception of their health. It is important to better understand these concerns, especially those currently [...]
Clinical Benefit of Docetaxel or Enzalutamide After Progression on First-Line Abiraterone and Prednisone in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) *
Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use [...]